Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
NCT07830719· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
NCT07387926· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
NCT07570979· Phase 1· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
NCT06675864· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886· Phase 1· Novartis Pharmaceuticals· Source